SLRN
ACELYRIN, INC. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website acelyrin.com
- Employees(FY) 108
- ISIN US00445A1007
Performance
-10.04%
1W
-14.59%
1M
-47.43%
3M
-50.34%
6M
-41.15%
YTD
-79.13%
1Y
Profile
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Investment Analysis Report: SLRN
Overview:
SLRN is a pharmaceutical company operating in the Health Technology sector with a market capitalization of $812,784,741. In this report, we will conduct a comprehensive analysis of SLRN's financial health, valuation, earnings and revenue growth, profitability, operating margin, operating cash flow, and ...
Technical Analysis of SLRN 2024-05-10
Overview:
In analyzing the technical indicators for SLRN over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming days.
Trend Analysis:
...Recent News & Updates
- 2024-05-14 23:54
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024(Investorplace)
- 2024-05-09 08:01
- 2024-05-09 08:00
ACELYRIN, INC. Announces Leadership Transition(GlobeNewswire)
- 2024-05-08 20:01
- 2024-05-08 20:00
ACELYRIN, INC. Announces Leadership Transition(Globenewswire)
- 2024-04-29 16:05
- 2024-04-29 04:05
- 2024-04-12 09:05
Acelyrin Insiders Placed Bullish Bets Worth US$2.65m(Simply Wall St.)
- 2024-03-28 16:05
- 2024-03-28 10:53
SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023(Investorplace)
- 2024-03-28 04:05
- 2024-03-27 16:01
- 2024-03-27 04:01
- 2024-03-20 23:12
- 2024-03-20 07:00
- 2024-03-20 00:39
- 2024-03-19 19:00
- 2024-03-11 08:02
- 2024-03-11 08:00
- 2024-03-10 22:04
- 2024-03-10 20:02
- 2024-03-10 20:00
- 2024-02-15 16:05
- 2024-02-15 03:05
- 2024-01-09 22:30
- 2024-01-03 20:56
- 2023-12-31 20:35
- 2023-12-26 21:45
- 2023-12-20 16:30
ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors(GlobeNewswire)
- 2023-12-20 03:30
ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors(globenewswire)
Page 1 of 3
previousnext